Nothing Special   »   [go: up one dir, main page]

SG11201903697WA - Liver organoid compositions and methods of making and using same - Google Patents

Liver organoid compositions and methods of making and using same

Info

Publication number
SG11201903697WA
SG11201903697WA SG11201903697WA SG11201903697WA SG11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA
Authority
SG
Singapore
Prior art keywords
cincinnati
international
liver
burnett
avenue
Prior art date
Application number
SG11201903697WA
Inventor
Takanori Takebe
Tadahiro Shinozawa
Masaki Kimura
Hiroyuki Koike
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of SG11201903697WA publication Critical patent/SG11201903697WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)

Abstract

Prearizedorvanoit( . . • • &waded CEMPINO. W O 18/085 6 15 Al FIG. I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT oimitia °nolo omm Holm onno oimIE (10) International Publication Number WO 2018/085615 Al (51) International Patent Classification: A61K 35/407 (2015.01) C12Q 1/00 (2006.01) C12N 5/00 (2006.01) G01N 33/50 (2006.01) C12N 15/01 (2006.01) (21) International Application Number: PCT/US2017/059845 (22) International Filing Date: 03 November 2017 (03.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/417,371 04 November 2016 (04.11.2016) US 62/517,414 09 June 2017 (09.06.2017) US (71) Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnett Avenue, Cincinnati, OH 45229 (US). (72) Inventors: TAKEBE, Takanori; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). SHINOZAWA, Tadahiro; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). KIMURA, Masaki; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). KOIKE, Hiroyuki; c/o 3333 Burnett Avenue, Cincinnati, Ohio 45229 (US). (74) Agent: TEPE, Nicole, M. et al.; Frost Brown Todd LLC, 3300 Great American Tower, 301 East Fourth Street, Cincinnati, OH 45202 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (54) Title: LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME (57) : Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and/or drug induced liver injury (DILI), and/or drug toxicity. The disclosed liver organoids may also be used to treat an individ- ual having liver damage, or for identifying a preferred therapeutic agent. [Continued on next page] WO 2018/085615 Al MIDEDIMOMMIDEFIE1111111111111111111111111011111111111111111111111111 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
SG11201903697WA 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same SG11201903697WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417371P 2016-11-04 2016-11-04
US201762517414P 2017-06-09 2017-06-09
PCT/US2017/059845 WO2018085615A1 (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
SG11201903697WA true SG11201903697WA (en) 2019-05-30

Family

ID=62076362

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903697WA SG11201903697WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same
SG10202104575WA SG10202104575WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202104575WA SG10202104575WA (en) 2016-11-04 2017-11-03 Liver organoid compositions and methods of making and using same

Country Status (11)

Country Link
US (4) US20200056157A1 (en)
EP (3) EP3534907A4 (en)
JP (4) JP7244418B2 (en)
KR (1) KR102546194B1 (en)
CN (3) CN110382012B (en)
AU (1) AU2017353982B2 (en)
CA (2) CA3041714A1 (en)
IL (1) IL266398A (en)
NZ (1) NZ753051A (en)
SG (2) SG11201903697WA (en)
WO (3) WO2018085615A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2015183920A2 (en) 2014-05-28 2015-12-03 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN116790476A (en) 2016-05-05 2023-09-22 儿童医院医疗中心 Methods for in vitro manufacturing of fundus tissue and compositions related thereto
KR20230110839A (en) 2016-12-05 2023-07-25 칠드런즈 호스피탈 메디칼 센터 Colonic organoids and methods of making and using same
CN110914408A (en) * 2017-06-09 2020-03-24 儿童医院医学中心 Liver organoid compositions and methods of making and using same
WO2019237124A1 (en) * 2018-06-09 2019-12-12 Arizona Board Of Regents On Behalf Of Arizona State University Next generation designer liver organoids and their methods of preparation and use
US20210324334A1 (en) * 2018-09-12 2021-10-21 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020069285A1 (en) * 2018-09-27 2020-04-02 Children's Hospital Medical Center Liver support system comprising liver organoids and methods of making and using same
JP7483233B2 (en) 2019-03-29 2024-05-15 国立大学法人 長崎大学 Cultured tissue and its manufacturing method
US20220220444A1 (en) * 2019-05-31 2022-07-14 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
JP7039045B2 (en) * 2019-08-26 2022-03-22 株式会社フェニックスバイオ Human fatty liver model cells
EP4118188A1 (en) 2020-03-11 2023-01-18 Bit Bio Limited Method of generating hepatic cells
CN113717850A (en) * 2020-05-26 2021-11-30 中国科学院大连化学物理研究所 Non-alcoholic fatty liver in-vitro model building method based on three-dimensional liver-like chip
WO2021243526A1 (en) * 2020-06-01 2021-12-09 苏州大学附属儿童医院 Use of specific marker lncrna for neonatal parenteral nutrition-associated liver disease
US20230235316A1 (en) * 2020-06-23 2023-07-27 Children's Hospital Medical Center Model for insulin resistance
EP4332215A1 (en) * 2021-04-28 2024-03-06 National University Corporation Tokyo Medical and Dental University Method for producing cells
US20230101335A1 (en) 2021-05-06 2023-03-30 Massachusetts Institute Of Technology Ex vivo tissue explant and graft platform and uses thereof
CN113430890A (en) * 2021-07-01 2021-09-24 驻马店市华中公路设计有限公司 Permanent composite pavement structure for old asphalt pavement reconstruction and construction device
CN115125187B (en) * 2022-06-14 2023-04-07 创芯国际生物科技(广州)有限公司 Organ-like in-vitro model of endometritis as well as establishment method and application thereof
CN115386535B (en) * 2022-10-26 2023-02-03 天津外泌体科技有限公司 Multispectral liver organoid model and drug hepatotoxicity evaluation method based on same
CN115418386B (en) * 2022-11-03 2023-03-24 成都诺医德医学检验实验室有限公司 Damage healing evaluation method based on skin organoid, model and application
WO2024185901A1 (en) * 2023-03-09 2024-09-12 国立大学法人 東京医科歯科大学 Composition for use in treating fatty liver disease
WO2024206911A2 (en) 2023-03-30 2024-10-03 Children's Hospital Medical Center Clinical-grade organoids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4666567B2 (en) 2001-12-07 2011-04-06 ジェロン・コーポレーション Islet cells derived from human embryonic stem cells
EP2722387B1 (en) 2003-12-23 2019-12-11 Viacyte, Inc. Definitive endoderm
SI2040713T1 (en) 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
DE602007012293D1 (en) * 2006-12-08 2011-03-10 Du Pont
PL3441458T3 (en) * 2009-02-03 2023-11-06 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) * 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
WO2010094694A1 (en) * 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Assays to predict cardiotoxicity
CA2755708A1 (en) 2009-03-17 2010-09-23 Axcan Pharma Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
JP5722885B2 (en) * 2009-06-18 2015-05-27 セレクティス アーベー 3D culture system for growth and differentiation of human pluripotent stem (hPS) cells
CN101696396A (en) * 2009-10-27 2010-04-21 中国人民解放军军事医学科学院卫生学环境医学研究所 Construction method and use of model of hepatitis B virus infection in vivo
KR20120118088A (en) * 2009-11-24 2012-10-25 앨더바이오 홀딩스 엘엘씨 Antibodies to il-6 and use thereof
JP5897543B2 (en) * 2010-03-22 2016-03-30 セルアーティス アーベー Differentiation induction and maturation from pluripotent cells to hepatocyte-like cells by regulating Wnt signaling pathway
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US20120291096A1 (en) * 2011-05-12 2012-11-15 Nokia Corporation Method and apparatus for secure signing and utilization of distributed computations
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
US20160237400A1 (en) * 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
US20160245653A1 (en) 2013-04-30 2016-08-25 Sangtae Park Cylindrical resonator gyroscope
CN105378064B (en) 2013-07-23 2021-05-04 公立大学法人横滨市立大学 Method for imparting vascular system to biological tissue
CN106488769A (en) 2014-03-21 2017-03-08 妥必徕疗治公司 For treating Fibrotic Sai Nikeweiluo
ES2764467T3 (en) 2014-04-11 2020-06-03 Cymabay Therapeutics Inc NAFLD and NASH Treatment
WO2015183920A2 (en) 2014-05-28 2015-12-03 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
DK3152296T3 (en) 2014-06-06 2021-11-08 Univ Brussel Vrije HUMAN HEPATIC 3D CULTURAL MODEL AND ITS APPLICATIONS
NZ728488A (en) 2014-07-29 2023-03-31 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
US20170304369A1 (en) * 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
CN104387451B (en) * 2014-11-07 2020-12-18 浙江海洋学院 Clam enzymolysis oligopeptide with repairing effect on non-alcoholic fatty liver disease cell model and preparation method thereof
AU2015353521B2 (en) * 2014-11-26 2021-11-04 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
CN107106873A (en) 2015-01-09 2017-08-29 吉利德阿波罗公司 ACC inhibitor combined therapies for treating non-alcoholic fatty liver disease
US20160256672A1 (en) * 2015-02-10 2016-09-08 Cedars-Sinai Medical Center Induced pluripotent stem cell-derived hepatocyte based bioartificial liver device
CN105985395A (en) 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 Obeticholic acid compound, and medicinal composition containing compound
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MA41083A1 (en) * 2015-04-07 2018-05-31 Intercept Pharmaceuticals Inc Pharmaceutical Compositions for Combination Therapy
US10557124B2 (en) * 2015-04-22 2020-02-11 The Regents Of The University Of Michigan Compositions and methods for obtaining stem cell derived lung tissue, and related uses thereof
PE20180690A1 (en) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc OBETICOLIC ACID COMPOSITIONS AND METHODS OF USE
CN108430220A (en) 2015-06-30 2018-08-21 巴斯夫农业公司阿纳姆(荷兰) A kind of composition and method of pest control
WO2017048193A1 (en) * 2015-09-15 2017-03-23 Agency For Science, Technology And Research (A*Star) Derivation of liver organoids from human pluripotent stem cells
SG10202002323UA (en) 2015-09-16 2020-05-28 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
US10801068B2 (en) 2015-10-16 2020-10-13 The Trustees Of Columbia University In The City Of New York JAG1 expression predicts therapeutic response in NASH
MX2018005540A (en) 2015-11-06 2018-11-09 Gemphire Therapeutics Inc Treatment of mixed dyslipidemia.
EP3426766B1 (en) * 2016-03-08 2022-12-28 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Method for continuous biosensing
EP3228306A1 (en) 2016-04-04 2017-10-11 ratiopharm GmbH Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
EP3445385A4 (en) 2016-04-18 2019-11-20 The Trustees of Columbia University in the City of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
KR20180129909A (en) 2016-04-22 2018-12-05 타이완제이 파마슈티컬스 컴퍼니 리미티드 Nalmefene, naltrexone or derivatives thereof for use in the treatment of (non) alcoholic fatty liver disease or nonalcoholic fatty liver disease
CN110914408A (en) 2017-06-09 2020-03-24 儿童医院医学中心 Liver organoid compositions and methods of making and using same

Also Published As

Publication number Publication date
CN117229994A (en) 2023-12-15
US20190298775A1 (en) 2019-10-03
CN110381967A (en) 2019-10-25
KR20190092394A (en) 2019-08-07
EP3534976A1 (en) 2019-09-11
US10668108B2 (en) 2020-06-02
EP3534919A4 (en) 2020-11-11
JP7078615B2 (en) 2022-05-31
KR102546194B1 (en) 2023-06-21
JP2019533452A (en) 2019-11-21
JP2023085289A (en) 2023-06-20
JP7545186B2 (en) 2024-09-04
CA3041712A1 (en) 2018-05-11
IL266398A (en) 2019-06-30
JP2019534006A (en) 2019-11-28
CN110382012B (en) 2023-08-25
EP3534907A4 (en) 2020-06-24
JP7244418B2 (en) 2023-03-22
US20210008123A1 (en) 2021-01-14
WO2018085615A1 (en) 2018-05-11
WO2018085622A1 (en) 2018-05-11
EP3534976A4 (en) 2020-09-16
US20190314387A1 (en) 2019-10-17
CA3041714A1 (en) 2018-05-11
JP2022119862A (en) 2022-08-17
WO2018085623A1 (en) 2018-05-11
EP3534907A1 (en) 2019-09-11
JP7576647B2 (en) 2024-10-31
US20200056157A1 (en) 2020-02-20
EP3534919A1 (en) 2019-09-11
AU2017353982B2 (en) 2021-05-06
NZ753051A (en) 2023-03-31
KR20230093079A (en) 2023-06-26
CN110382012A (en) 2019-10-25
SG10202104575WA (en) 2021-06-29
AU2021212060A1 (en) 2021-08-26
AU2017353982A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201809051YA (en) Cell retention device and method
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900361RA (en) Methods of treating prostate cancer
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201805170XA (en) Cellular glycosaminoglycan compositions and methods of making and using
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201805788WA (en) Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
SG11201906852XA (en) Treatment of diuretic resistance